Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079)

Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers

(2014) T. A. Yap et al.   CLINICAL CANCER RESEARCH

Characterization of the Novel and Specific PI3K  Inhibitor NVP-BYL719 and Development of the Patient Stratification Strategy for Clinical Trials

(2014) C. Fritsch et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical evaluation of the mTOR–PI3K inhibitor BEZ235 in nasopharyngeal cancer models

(2013) Brigette B.Y. Ma et al.   CANCER LETTERS

PIK3CA and AKT1 Mutations Have Distinct Effects on Sensitivity to Targeted Pathway Inhibitors in an Isogenic Luminal Breast Cancer Model System

(2013) J. A. Beaver et al.   CLINICAL CANCER RESEARCH

Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 Has a Therapeutic Potential and Sensitizes Cisplatin in Nasopharyngeal Carcinoma

(2013) Fen Yang et al.   PLoS One

Frequent Mutation of the PI3K Pathway in Head and Neck Cancer Defines Predictive Biomarkers

(2013) V. W. Y. Lui et al.   Cancer Discovery

Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer

(2013) L-Y Huw et al.   Oncogenesis

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

(2012) T. Sangai et al.   CLINICAL CANCER RESEARCH

Phosphoinositide 3-Kinase (PI3K) Pathway Alterations Are Associated with Histologic Subtypes and Are Predictive of Sensitivity to PI3K Inhibitors in Lung Cancer Preclinical Models

(2012) J. M. Spoerke et al.   CLINICAL CANCER RESEARCH

Preclinical evaluation of the AKT inhibitor MK-2206 in nasopharyngeal carcinoma cell lines

(2012) Brigette B. Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation

(2011) E. P. Hui et al.   ANNALS OF ONCOLOGY

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma

(2011) Wan-Teck Lim et al.   CLINICAL CANCER RESEARCH

First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Plasma EBV DNA Clearance Rate as a Novel Prognostic Marker for Metastatic/Recurrent Nasopharyngeal Carcinoma

(2010) W.-Y. Wang et al.   CLINICAL CANCER RESEARCH

PIK3CA amplification is predictive of poor prognosis in Tunisian patients with nasopharyngeal carcinoma

(2009) Ali Fendri et al.   CANCER SCIENCE

The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell lines

(2009) Brigette B. Y. Ma et al.   INVESTIGATIONAL NEW DRUGS

Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

(2008) Brigette B. Y. Ma et al.   CANCER SCIENCE

Nasopharyngeal carcinoma—Review of the molecular mechanisms of tumorigenesis

(2008) Josephine Chou et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK